MALAT1 and MEG3 genes expression in non-alcoholic fatty liver disease in type 2 diabetes mellitus patients: a case-control study

References

• Pouwels S, Sakran N, Graham Y, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022;22(1):63. doi: 10.1186/s12902-022-00980-1
   PubMed Web of Science ®Google Scholar
• Younossi ZM. Non-alcoholic fatty liver disease - a global public health perspective. J Hepatol. 2019;70(3):531–544. doi: 10.1016/j.jhep.2018.10.033
   PubMed Web of Science ®Google Scholar
• Henry L, Paik J, Younossi ZM. Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world. Aliment Pharmacol Ther. 2022;56(6):942–956. doi: 10.1111/apt.17158
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Marchesini G, Pinto-Cortez H, et al. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: implications for liver transplantation. Transplantation. 2019;103(1):22–27. doi: 10.1097/TP.0000000000002484
   PubMed Web of Science ®Google Scholar
• Ramraj B, Duraisamy R, Kumar MPS. Complications of diabetes mellitus: a review. Drug Invent Today. 2019;12:98–103.
   Google Scholar
• Mallet V, Parlati L, Martinino A, et al. Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus. J Hepatol. 2022;76(2):265–274. doi: 10.1016/j.jhep.2021.09.030
   PubMed Web of Science ®Google Scholar
• García-Compeán D, Kumar R, Cueto-Aguilera Á ND, et al. Body weight loss and glycemic control on the outcomes of patients with NAFLD. The role of new antidiabetic agents. Annals Of Hepatology. 2022;28(4):100751. doi: 10.1016/j.aohep.2022.100751
   PubMed Web of Science ®Google Scholar
• Martínez-Arranz I, Bruzzone C, Noureddin M, et al. Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles. Hepatology. 2022;76(4):1121–1134. doi: 10.1002/hep.32427
   PubMed Web of Science ®Google Scholar
• Martin A, Lang S, Goeser T, et al. Management of dyslipidemia in patients with non-alcoholic fatty liver disease. Curr Atheroscler Rep. 2022;24(7):533–546. doi: 10.1007/s11883-022-01028-4
   PubMed Web of Science ®Google Scholar
• Chung W, Promrat K, Wands J. Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases. World J Hepatol. 2020;12(9):533–557. doi: 10.4254/wjh.v12.i9.533
   PubMed Web of Science ®Google Scholar
• Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut. 2021;70(5):962–969. doi: 10.1136/gutjnl-2020-322572
   PubMed Web of Science ®Google Scholar
• Hoang SA, Oseini A, Feaver RE, et al. Gene expression predicts histological severity and reveals distinct molecular profiles of nonalcoholic fatty liver disease. Sci Rep. 2019;9(1):12541. doi: 10.1038/s41598-019-48746-5
   PubMedGoogle Scholar
• Cai C, Song X, Yu C. Identification of genes in hepatocellular carcinoma induced by non-alcoholic fatty liver disease. Cancer Biomark. 2020;29(1):69–78. doi: 10.3233/CBM-190169
   PubMed Web of Science ®Google Scholar
• Hyun J, Jung Y. DNA methylation in nonalcoholic fatty liver disease. Int J Mol Sci. 2020;21(21):8138. doi: 10.3390/ijms21218138
   PubMed Web of Science ®Google Scholar
• Dhamija E, Paul SB, Kedia S. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: an increasing concern. Indian J Med Res. 2019;149(1):9–17. doi: 10.4103/ijmr.IJMR_1456_17
   PubMed Web of Science ®Google Scholar
• Abdo Gabali M, SAEED O. Study of prevalence of nonalcoholic fatty liver disease in type II diabetes mellitus patients and variations in liver enzymes and lipid profile in diabetic patients with fatty liver in comparison with patients without fatty liver. Med J Cairo Univ. 2019 March;87(March):687–691. doi: 10.21608/mjcu.2019.52525
   Google Scholar
• Gutiérrez-Cuevas J, Lucano-Landeros S, López-Cifuentes D, et al. Epidemiologic, genetic, pathogenic, metabolic, epigenetic aspects involved in NASH-HCC: current therapeutic strategies. Cancers (Basel). 2022;15(1):23. doi: 10.3390/cancers15010023
   PubMed Web of Science ®Google Scholar
• Prasad K, Gupte S. Non alcoholic fatty liver disease (NAFLD) in type 2 diabetes mellitus patients-significance of ALT. Int J Health Clin Res. 2014;3(12):281–283.
   Google Scholar
• Shrestha N, Bhatt NP, Neopane P, et al. Hepatic involvement with elevated liver enzymes in Nepalese subjects with type 2 diabetes mellitus. Int J Biochem Res Rev. 2017;16(1):1–8. doi: 10.9734/IJBCRR/2017/31935
   Google Scholar
• Cai J, Zhang XJ, Ji YX, et al. Nonalcoholic fatty liver disease pandemic fuels the upsurge in cardiovascular diseases. Circ Res. 2020;126(5):679–704. doi: 10.1161/CIRCRESAHA.119.316337
   PubMed Web of Science ®Google Scholar
• Anoop S, Misra A, Bhatt SP, et al. High fasting C-peptide levels and insulin resistance in non-lean & non-obese (BMI >19 to < 25 kg/m(2)) Asian Indians with type 2 diabetes are independently associated with high intra-abdominal fat and liver span. Diabetes Metab Syndr. 2019;13(1):708–715. doi: 10.1016/j.dsx.2018.11.041
   PubMed Web of Science ®Google Scholar
• Sathishkumar C, Prabu P, Mohan V, et al. Linking a role of lncRnas (long non-coding RNAs) with insulin resistance, accelerated senescence, and inflammation in patients with type 2 diabetes. Hum Genomics. 2018;12(1):41. doi: 10.1186/s40246-018-0173-3
   PubMed Web of Science ®Google Scholar
• Yu F, Lu Z, Cai J, et al. MALAT1 functions as a competing endogenous RNA to mediate Rac1 expression by sequestering miR-101b in liver fibrosis. Cell Cycle. 2015;14(24):3885–3896. doi: 10.1080/15384101.2015.1120917
   PubMed Web of Science ®Google Scholar
• Kim YA, Park KK, Lee SJ. LncRNAs act as a link between chronic liver disease and hepatocellular carcinoma. Int J Mol Sci. 2020;21(8):2883. doi: 10.3390/ijms21082883
   PubMed Web of Science ®Google Scholar
• Leti F, Legendre C, Still CD, et al. Altered expression of MALAT1 lncRNA in nonalcoholic steatohepatitis fibrosis regulates CXCL5 in hepatic stellate cells. Transl Res. 2017;190:25–39. doi: 10.1016/j.trsl.2017.09.001
   PubMed Web of Science ®Google Scholar
• Khalifa O, Errafii K, Al-Akl NS, et al. Noncoding RNAs in nonalcoholic fatty liver disease: potential diagnosis and prognosis biomarkers. Dis Markers. 2020;2020:8822859. doi: 10.1155/2020/8822859
   PubMed Web of Science ®Google Scholar